US 11,813,279 B2
Compositions for cancer therapy and methods
David R. Strayer, Ocala, FL (US); and Thomas K. Equels, Ocala, FL (US)
Assigned to AIM ImmunoTech Inc., Ocala, FL (US)
Filed by AIM IMMUNOTECH INC., Ocala, FL (US)
Filed on Aug. 9, 2019, as Appl. No. 16/537,442.
Claims priority of provisional application 62/869,909, filed on Jul. 2, 2019.
Claims priority of provisional application 62/792,796, filed on Jan. 15, 2019.
Claims priority of provisional application 62/792,786, filed on Jan. 15, 2019.
Claims priority of provisional application 62/792,783, filed on Jan. 15, 2019.
Claims priority of provisional application 62/792,778, filed on Jan. 15, 2019.
Claims priority of provisional application 62/792,765, filed on Jan. 15, 2019.
Claims priority of provisional application 62/792,812, filed on Jan. 15, 2019.
Claims priority of provisional application 62/792,788, filed on Jan. 15, 2019.
Claims priority of provisional application 62/792,770, filed on Jan. 15, 2019.
Claims priority of provisional application 62/792,791, filed on Jan. 15, 2019.
Claims priority of provisional application 62/792,760, filed on Jan. 15, 2019.
Claims priority of provisional application 62/783,834, filed on Dec. 21, 2018.
Prior Publication US 2020/0197433 A1, Jun. 25, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/713 (2006.01); A61K 38/21 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); A61K 9/00 (2006.01); A61K 39/00 (2006.01)
CPC A61K 31/713 (2013.01) [A61K 9/0019 (2013.01); A61K 38/212 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01); A61K 2039/505 (2013.01)] 29 Claims
 
1. A method for treating a cancer selected from the group consisting of: pancreatic cancer; renal cell carcinoma; colorectal cancer and melanoma, in a subject in need thereof, the method comprising: administering to the subject at least a first compound and a second compound together or separately, wherein the first compound comprises an effective amount of an anti-PD-L1 antibody optionally with at least one pharmaceutically-acceptable carrier, and wherein the second compound is an effective amount of rintatolimod optionally with at least one pharmaceutically-acceptable carrier.